ADEF
RNTX

ABS Direct Equity Fund’s Rein Therapeutics RNTX Stock Holding History

ABS Direct Equity Fund’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Hold
125,000
– – 0.08% 106
2026
Q1 		$163K Hold
125,000
– – 0.12% 93
2025
Q4 		$145K Buy
+125,000
New +$172K 0.17% 35

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

ABS Direct Equity Fund's RNTX Position: Q2 2026 in Review

ABS Direct Equity Fund held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 125,000 shares worth $130K. The position accounts for 0.08% of the portfolio, ranked #106.

ABS Direct Equity Fund first reported a position in RNTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $163K in Q1 2026. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • ABS Direct Equity Fund held 125,000 shares of Rein Therapeutics worth $130K as of Q2 2026.
  • ABS Direct Equity Fund left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up 0.08% of ABS Direct Equity Fund's portfolio in Q2 2026, its #106 holding.
  • ABS Direct Equity Fund first reported a position in Rein Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • ABS Direct Equity Fund's Rein Therapeutics position peaked at $163K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.